Effect of Xuesaitong Soft Capsules on Major Risk Factors in Patients With Coronary Heart Disease

Lab values

• Patients fulfilling any of the following criteria are not eligible for inclusion in this trial:
  • Acute coronary syndrome occurred or received percutaneous coronary intervention therapy within the past 3 months
  • Previously received coronary artery bypass grafting
  • Stroke occurred within the previous 3 months
  • Symptomatic heart failure (HF) in the past, or documented left ventricular ejection fraction \< 35%
  • Revascularization or surgical procedures are planned within the next 3 months
  • Progressive neuromuscular disease, or creatine kinase (CK) levels \> 3 times the normal upper limit (ULN)
  • Lupus, inflammatory bowel disease, severe arthritis and other inflammatory diseases
  • Immunosuppressants such as cyclosporine, tacrolimus, azathioprine, or systemic steroids are currently being taken or planned during the study
  • History of hereditary dyslipidemia such as familial hypercholesterolemia
  • There has been a change in lipid regulation treatment within the past 1 month, or there is a current adjustment plan
  • History of symptomatic non-traumatic cerebral hemorrhage at any time in the past
  • History of gastrointestinal bleeding or major surgery within the past 6 months
  • Use of Xuesaitong soft capsules or preparations containing the main ingredients of Xuesaitong in the past 1 month
  • There were clear adverse reactions to the main components of Xuesaitong in the past
  • Active liver disease, or alanine aminotransferase (ALT) levels \> 3 times the upper limit of normal (ULN)
  • Chronic kidney disease, or estimated glomerular filtration rate (eGFR) \<60ml/ (min×1.73m2)
  • Pregnancy or planned pregnancy, or breastfeeding
  • Malignant tumors, or other serious diseases with an estimated survival of less than 1 year
  • Mental disorders or communication disorders, cognitive impairment, or other serious medical conditions that may affect study participation
  • Have participated in or are participating in other clinical trials within the last 1 month
  • Poor adherence to follow-up or medication is known

• Age ≥18 years old
• Chronic coronary artery disease: meet any of the following conditions, and the condition is stable for at least 3 months:
  • History of myocardial infarction
  • Have received coronary interventional therapy
  • There are symptoms of myocardial ischemia (such as chest pain) and objective evidence (stress electrocardiogram or stress myocardial perfusion imaging indicated myocardial ischemia or coronary artery stenosis ≥50% )
• High-sensitivity C-reactive protein ≥2mg/L
• Currently taking moderate or above intensity statins lipid-lowering drugs
• Currently taking antiplatelet drugs
• Sign informed consent